# US 11,111,316 B2 · Chitosan-derived compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,316 B2
- Document ID: US11111316B2
- Status: Granted
- Kind: B2
- Application number: 16/028,221
- Filed: 2018-07-05
- Published: 2018-11-01
- Granted: 2021-09-07
- Earliest claimed: 2012-01-20
- Assignees: Immunophotonics, Inc.
- Applicants: Immunophotonics, Inc.
- Inventors: Tomas Hode; Robert Nordquist; Wei R. Chen; Raoul Carubelli; Luciano Alleruzzo; Peter Jenkins; Kristopher Waynant; Joseph Raker
- Web page: https://patentgrep.com/patent/US11111316B2

## CPC

- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- A61B 18/20: using laser
- A61K 31/722: Chitin, chitosan
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 35/00: Antineoplastic agents
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/812: {Breast}
- A61K 2039/86: {Lung}
- A61K 2039/884: {prostate}
- A61N 5/0618: {Psychological treatment}
- A61N 5/0624: {for eliminating microbes, germs, bacteria on or in the body}
- A61N 5/067: using laser light
- A61N 2005/0659: {infrared}
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

## Claims

### Claim 1

A pharmaceutical formulation comprising a glycated chitosan having a molecular weight of about 100,000 to about 300,000 Daltons; wherein the glycated chitosan has a degree of deacetylation of about 75% to about 99% and a degree of glycation of free amino groups of about 0.1% to about 30%; and further wherein the pharmaceutical formulation is a sterile aqueous solution formulated for injection, and further wherein either:
the glycated chitosan has a molecular weight of about 250,000 Daltons; or
the glycated chitosan has a degree of glycation of about 2-7% or about 12.5%.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the glycated chitosan has a molecular weight of about 250,000 Daltons.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the degree of glycation is about 2-7%.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the degree of glycation is about 2% or about 12.5%.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the degree of deacetylation is about 80%.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the aqueous solution comprises a buffered physiological saline solution.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the aqueous formulation has a pH of about 5.0 to about 7.0.

### Claim 8 (depends on 7)

The pharmaceutical formulation of claim 7, wherein the aqueous formulation has a pH of about 5.0.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation comprises about 0.5%, about 1%, or about 1.5% by weight of the glycated chitosan.

### Claim 10 (depends on 9)

The pharmaceutical formulation of claim 9, wherein the pharmaceutical formulation comprises about 1% by weight of the glycated chitosan.

### Claim 11 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is sterile filtered.

### Claim 12

A method of generating an in situ autologous vaccine, comprising: ablating a neoplasm in a host, thereby releasing fragmented neoplastic tissue and cellular molecules; and introducing a pharmaceutical formulation comprising a glycated chitosan into the neoplasm, wherein:
the glycated chitosan has a molecular weight of about 100,000 to about 300,000 Daltons;
the glycated chitosan has a degree of deacetylation of about 75% to about 99%; and
the glycated chitosan has a degree of glycation of free amino groups of about 0.1% to about 30%.

### Claim 13

A method of enhancing immune system response to an antigen in a patient in need thereof, comprising administering a pharmaceutical formulation comprising a glycated chitosan into the neoplasm, wherein:
the glycated chitosan has a molecular weight of about 100,000 to about 300,000 Daltons;
the glycated chitosan has a degree of deacetylation of about 75% to about 99%; and
the glycated chitosan has a degree of glycation of free amino groups of about 0.1% to about 30%.

### Claim 14 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the degree of glycation is about 7%.

### Claim 15 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the glycated chitosan has a molecular weight of about 250,000 Daltons, and a degree of deacetylation of about 80%.

### Claim 16 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation consists essentially of a glycated chitosan having a molecular weight of about 100,000 to about 300,000 Daltons; wherein the glycated chitosan has a degree of deacetylation of about 75% to about 99% and a degree of glycation of free amino groups of about 0.1% to about 30%; and further wherein the pharmaceutical formulation is an aqueous solution formulated for injection.

### Claim 17 (depends on 16)

The pharmaceutical formulation of claim 16, wherein the glycated chitosan has a molecular weight of about 250,000 Daltons.

### Claim 18 (depends on 16)

The pharmaceutical formulation of claim 16, wherein the glycated chitosan has a degree of deacetylation is about 80%.

### Claim 19 (depends on 16)

The pharmaceutical formulation of claim 16, wherein the glycated chitosan has a molecular weight of about 250,000 Daltons and a degree of deacetylation of about 80%.